In a significant move for the pharmaceutical industry, the Food and Drug Administration on Thursday proposed excluding the active ingredients in blockbuster weight loss and diabetes drugs from Novo Nordisk and Eli Lilly from a list allowing bulk compounding by outsourcing facilities. The proposal, if finalized, would restrict the mass production of cheaper, custom versions of these medications unless they are listed on the FDA's drug shortage list, marking a clear victory for the two companies that have dominated the market for these popular treatments.
The affected drugs include semaglutide, the key ingredient in Novo's obesity treatment Wegovy and its diabetes counterpart Ozempic, as well as tirzepatide, found in Lilly's weight loss injection Zepbound and diabetes shot Mounjaro. The proposal also covers Novo's older molecule, liraglutide, used in treatments like Saxenda for weight management. According to the FDA's release, the agency has determined there is "no clinical need" for outsourcing facilities to compound these drugs from bulk substances when FDA-approved versions are available.
FDA Commissioner Marty Makary emphasized the regulatory boundaries in a statement, saying, "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." This proposal specifically targets 503B outsourcing facilities, which are allowed to manufacture compounded drugs in large quantities, often without individual prescriptions, and fall under federal FDA oversight. In contrast, the rules do not apply to 503A pharmacies, which prepare compounded medications tailored to specific patient prescriptions and are primarily regulated by state authorities.
The decision comes amid a surge in demand for GLP-1 receptor agonists like semaglutide and tirzepatide, which have transformed treatments for obesity and type 2 diabetes. These drugs, mimicking hormones that regulate blood sugar and appetite, have seen prescriptions skyrocket in recent years, with millions of Americans turning to them for weight loss. Novo Nordisk and Eli Lilly have reported combined annual sales exceeding $20 billion for these products, but supply shortages in 2022 and 2023 led many patients to seek out compounded alternatives, which are often 50% to 70% cheaper than the branded versions.
To address these shortages, both companies have poured billions into expanding manufacturing capacity. Novo Nordisk, for instance, announced investments of over $6 billion in U.S. production facilities in states like North Carolina and Ohio, aiming to boost output of semaglutide by 2025. Eli Lilly has similarly committed more than $9 billion to new plants in Indiana and North Carolina, with executives stating in recent earnings calls that these efforts have already increased supply by over 50% in the past year. These expansions have helped ease constraints, allowing the FDA to now argue against the need for bulk compounding.
The proposal arrives as the companies have also ramped up efforts to make their branded drugs more accessible. Novo Nordisk introduced a direct-to-consumer savings card that caps monthly costs at $25 for eligible patients, while Eli Lilly launched a similar program offering Zepbound for as low as $399 per month without insurance. These initiatives aim to recapture market share from compounding pharmacies, which have proliferated in response to high demand and initial shortages. Industry analysts estimate that compounded versions accounted for up to 20% of the GLP-1 market at its peak in 2023.
Under current FDA guidelines, outsourcing facilities can compound drugs using bulk ingredients only if the final product is essentially a copy of an approved drug and there's a documented shortage or clinical necessity. The agency's proposal would add semaglutide, tirzepatide, and liraglutide to a list of exclusions, effectively barring bulk compounding unless shortages reemerge. The FDA plans to accept public comments on the proposal until late June, after which it will review input from stakeholders including patients, pharmacies, and drugmakers before issuing a final rule, potentially by the end of 2026.
Representatives from Novo Nordisk and Eli Lilly did not immediately respond to requests for comment on Thursday, but in past statements, both companies have supported stricter regulations on compounding to protect patient safety. Compounded versions of these drugs have faced scrutiny for quality issues; earlier this year, the FDA warned of adverse events linked to some compounded semaglutide products, including nausea, vomiting, and even hospitalizations due to dosing errors or contamination. The agency has issued multiple alerts since 2023, urging consumers to stick with FDA-approved medications.
Patient advocacy groups have mixed reactions to the proposal. The Obesity Action Coalition, a nonprofit representing those affected by obesity, welcomed the move in a preliminary statement, noting that FDA-approved drugs undergo rigorous testing for safety and efficacy. "Access to reliable medications is crucial, and this helps ensure patients get treatments backed by science," said a spokesperson. However, some independent pharmacists argue that compounding remains vital for patients who can't afford branded drugs or need customized dosages. The National Community Pharmacists Association has previously lobbied for flexibility in compounding rules, citing the high cost of branded GLP-1s, which can exceed $1,000 per month without insurance.
The broader context of this proposal ties into ongoing debates over drug pricing and access in the U.S. Lawmakers on both sides of the aisle have pushed for reforms, with the Inflation Reduction Act of 2022 enabling Medicare to negotiate prices for high-cost drugs, including some insulins but not yet GLP-1s. Meanwhile, the rise of these weight loss drugs has spotlighted the obesity epidemic, affecting over 40% of American adults according to Centers for Disease Control and Prevention data. Experts predict the market for these therapies could reach $100 billion globally by 2030, driving intense competition and regulatory attention.
From a regulatory standpoint, the FDA's action aligns with its post-pandemic efforts to crack down on unauthorized compounding, which exploded during COVID-19 supply disruptions. In 2020, the agency temporarily allowed bulk compounding for certain drugs in short supply, but has since tightened controls to prevent counterfeit or substandard products from flooding the market. This proposal builds on a 2024 interim rule that already restricted compounding of certain semaglutide copies, following lawsuits from Novo Nordisk accusing compounders of patent infringement.
Legal battles have been fierce, with Novo and Lilly filing suits against numerous compounding pharmacies and even telemedicine providers offering knockoff versions. A federal court in Texas ruled in favor of Novo in December 2024, blocking a major compounder from producing semaglutide copies, a decision that bolstered the companies' positions. Eli Lilly has pursued similar litigation, resulting in settlements and shutdowns of several operations. These court wins, combined with improved supply, have shifted the landscape, making the FDA's proposal a timely reinforcement.
Looking ahead, the proposal's finalization could reshape the compounding industry, potentially leading to closures for some 503B facilities that rely heavily on GLP-1 production. Economists estimate the compounded market for these drugs generates hundreds of millions in annual revenue, supporting jobs in pharmacy and manufacturing sectors across states like California and Florida, where many facilities are based. If shortages recur—say, due to unexpected demand spikes—the FDA could reinstate compounding allowances, providing a safety valve for patients.
For consumers, the implications are twofold: greater assurance of drug quality from approved sources, but possibly higher costs if compounded options vanish. Public health officials stress that while these drugs offer life-changing benefits, they must be used under medical supervision to mitigate risks like gastrointestinal side effects or muscle loss. As comments pour in over the next two months, the FDA's decision will likely influence not just Novo and Lilly's bottom lines, but the future of personalized medicine in America.
In the end, this proposal underscores the tension between innovation, affordability, and safety in the pharmaceutical world. With obesity rates climbing and diabetes diagnoses rising, the stakes are high for all involved. Stakeholders from Washington to Wall Street will watch closely as the FDA weighs the input that could finalize these restrictions by year's end.